From oocytes to euploid embryos: does recombinant LH make a difference?

Marcos Meseguer poses a practical question: does adding recombinant LH change the path from oocyte to euploid embryo? He answers it not with opinion but with data — analysing a real clinical cohort with artificial intelligence.

The basis is a retrospective study of about 300 patients, over 1,000 oocytes per group. What was assessed was not the mere number of retrieved cells but the oocyte-to-euploid-embryo conversion: how many euploid blastocysts ultimately arise from the starting material. This is the metric that reflects clinically meaningful stimulation efficiency.

The key result: AI analysis detected 2.3× more euploid blastocysts with recombinant FSH combined with LH than with human menopausal gonadotropin (hMG). The difference concerns not oocyte count as such but the oocytes' capacity to yield a genetically sound embryo.

Mechanistically this fits LH's role in final maturation and in supporting oocyte cytoplasmic quality: nuclear and cytoplasmic maturation are relatively independent, and it is precisely the "invisible" cytoplasmic immaturity that often underlies a low euploidy rate. Adequate LH support shifts the balance toward competent oocytes.

A separate thread is the method itself. The headline phrase — "Precision is no longer an ad; now it's just a question of computation" — captures the shift: AI can objectively assess, at scale, what the human eye judges unreliably, turning "precision" from marketing into a measurable quantity.

The caveats matter. The study is retrospective, from a single centre, and between-group differences may partly reflect patient selection and protocol factors. Such data generate a hypothesis and set a direction for prospective testing rather than serving as definitive proof.